Lakefront completes sale of preclinical CAR — T programs to Armed Cell Therapeutics

Lakefront Biotherapeutics completed the sale of its preclinical cell therapy pipeline to Belgium-based Armed Cell Therapeutics on October 14, 2026. Terms include an upfront payment of €8 million, potential milestone payments of up to $230 million and a low-single-digit royalty. The transferred assets include multi-targeting and armed CAR-T constructs targeting blood cancers and solid tumors. Armed Cell Therapeutics will independently advance the programs. * The previously planned wind-down of legacy cell therapy activities is substantially complete. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lakefront Biotherapeutics NV published the original content used to generate this news brief via (Ref. ID: 202610141601PRIMZONEFULLFEED1001278027) on October 14, 2026, and is solely responsible for the information contained therein. (C)